Emergent BioSolutions Inc. (EBS)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$7.24+14.38%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $371M
- Forward P/E
- 6.9
- 52-week range
- $4.36 – $14.06
- 52-week change
- −30.74%
- EPS (trailing)
- −$3.40
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $743M (−28.81%)
- Net income
- $52.6M
- Operating margin
- 13.5%
- Diluted EPS
- $0.93
- Free cash flow
- $157M
From the company’s annual report on SEC EDGAR.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from…
Headquarters: Gaithersburg, United States · 900 employees · emergentbiosolutions.com